What Is Milo Biotechnology?

Milo Biotechnology is developing therapies for the treatment of muscular dystrophy that increase muscle strength or decrease the rate of muscle atrophy.

The biotechnology company’s core technology, a gene therapy-based up-regulation of the muscle-strengthening follistatin protein, was developed at and is exclusively licensed from Nationwide Children’s Hospital.

Milo Biotechnology is based in Cleveland, Ohio, and has received seed funding from JumpStart Inc., the Cuyahoga County North Coast Opportunities Fund and a grant from NIH-NIAMS rare diseases SBIR program. In late 2012, the company received FDA Orphan Drug Designation for its treatment for Duchenne and Becker Muscular Dystrophy.

Read More

Recent News


Preliminary Findings in Milo Follistatin Gene Transfer Study Promising

Preliminary results from a trial to test the safety of injecting follistatin genes into the thigh muscles of adults with... Read More →

Combined therapy could repair and prevent damage in Duchenne muscular dystrophy

New research on two promising gene therapies suggests that combining them into one treatment not only repairs muscle damage caused... Read More →
Back to Top